NEW HAVEN, Conn. - 利用人工智能进行神经科学药物开发的生物制药公司BioXcel Therapeutics, Inc. (NASDAQ:BTAI)最近宣布了其临床项目优先级的战略调整。该公司选择专注于BXCL501的后期开发项目,该药物用于治疗与双相情感障碍、精神分裂症和阿尔茨海默病相关的躁动,同时缩减其已获批药物IGALMI™(地美地啶)舌下膜的商业化努力。 周一开始的SERE ...
We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking “Accept,” you agree to our ...